Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) on Thursday said it has entered into a licensing and commercialization agreement with a strategic partner in Malaysia for its denosumab biosimilars MAILISHU and MAIWEIJIAN.
Under the agreement, the partner will handle registration and commercialization in Malaysia, while Mabwell will be responsible for development, manufacturing and supply of the products.
MAILISHU, a biosimilar of Amgen's Prolia, has been approved by National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis, while MAIWEIJIAN, a biosimilar of Amgen's Xgeva, has been approved by the NMPA for giant cell tumor of the bone.
"Malaysia has an internationally aligned regulatory environment, strong regional recognition and significant space for development. This collaboration will further deepen Mabwell's presence in the ASEAN market. We look forward to rapidly advancing the product's local registration and commercialization with our partner's strong commercial capabilities, bring high-quality, affordable treatment options to more patients in the region," Huiguo Hu, Board Member, Senior Vice President and Board Secretary of Mabwell, said.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.